HistoSonics, Inc.
11
4
7
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
18.2%
2 terminated/withdrawn out of 11 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
200%
4 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Role: lead
The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy
Role: lead
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
Role: collaborator
The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
Role: lead
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)
Role: lead
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
Role: lead
The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
Role: lead
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
Role: lead
Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
Role: lead
Study to Evaluate VORTX Rx (Theresa)
Role: lead
Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)
Role: lead
All 11 trials loaded